Please Wait.....
Report
Antibiotics: Technologies and Global Markets
Market Research Report I 2023-05-18 I 150 Pages I BCC Research
Description
Report Scope:
This report is focused on newer drugs and innovations in chemical compounds, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control, drugs used for symptomatic treatment and not for the elimination of the virus from the host and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potential of antibiotics with detailed analysis of the competitive environment. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment are covered, along with a market projection for 2027 and market share assessment for key players.
The report segments the market for antibiotics based on product type, route of administration, application and geographical region. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA and other inhibitors (RNA, mycolic acid, folic acid). Based on route of administration, the market is segmented into oral and topical.
By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa. Detailed analysis of major countries (U.S., Germany, UK, Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa) will be covered in the regional segment. For market estimates, data will be provided for 2021 as the base year, with estimates for 2022 and forecast value for 2027.
Report Includes:
- 22 data tables and 16 additional tables
- An overview of the global market for antibiotics within the pharmaceutical industry
- Analyses of the global market trends, with data corresponding to market size for 2019-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
- Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user, and geographical region
- Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
- Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
- Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc. and Sanofi
Executive Summary
Summary:
The global market for antibiotics was valued at $39.2 billion in 2021. The market is expected to grow at a compound annual growth rate (CAGR) of 4.2% to reach $49.6 billion by the end of 2027. The antibiotic market growth outlook is positive with significant growth potential for cell wall inhibitor and protein inhibitor antibiotic drugs. There is pressure on antibiotic drug manufacturers to offer antimicrobialresistant drugs at affordable prices. At the same time, factors such as rising disposable incomes and increasing spending on healthcare in emerging markets, increasing grants from government agencies for antibiotic drugs R&D and rising incidence of infectious diseases are contributing to the growth of the market.
Pharmaceutical companies and governments are increasingly working together in partnerships and collaborations to provide funding and to implement incentive programs for the R&D of antibiotics. These partnerships provide financial and technical assistance across different clinical development phases. Various programs, such as the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), the Innovative Medicines Initiative's (IMI's) New Drugs for Bad Bugs (ND4BB) program, Biomedical Advanced Research and Development Authority's (BARDA) Broad Spectrum Antimicrobials Program and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), have been implemented for the development of novel antibiotics by focusing on R&D gaps.
Additionally, The Davos Declaration was signed in Jan. 2016 by more than 100 companies and trade associations (Allergan, AstraZeneca, GSK, Pfizer and Sanofi). This declaration focused on investments in R&D to meet public health needs, reducing the development of antimicrobial resistance and improving access to antibiotics.
Pharmaceutical companies are increasingly adopting 3D printing technology for the discovery and development of new antibiotics to reduce manufacturing costs and increase production efficiency. In 2018, a 3D-printed fluorescence imaging box (PFIbox) was developed by McMaster University's laboratory for antibiotics discovery. This box is capable of analyzing more than 6,000 samples of bacteria at a time and provides vital information on bacterial response.
The global antibiotic market is segmented based on the product, route of administration, end user and region.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Overview of Antibiotics
Common Side Effects of Antibiotics
Classification of Antibiotics
Cell Wall Inhibitors
Protein Inhibitors
DNA Inhibitors
Other Antibiotic Classes
Antibiotic Classification, by Source
Overview of Gram-Negative and Gram-Positive Bacteria
Route of Administration
Trends in the Market for Antibiotics
New Antibiotic Development
Antibiotic Drug Development, Smaller Pharmaceutical Firms
Growing Public/Private Partnerships
Chapter 4 Market Dynamics
Market Drivers
Growth Driven by Antibiotics
Rising Elder Population and Infection Rate
Increasing Hospital-acquired Infections
Improved Awareness
Market Restraints
Antibiotic-resistant Infections
Generics
Declining R&D Investment
Side Effects of Antibiotics
Market Opportunities
Market Expansion
Novel Antibacterial Agents
Chapter 5 Market Breakdown, by Product
Global Market for Antibiotics by Product
Cell Wall Inhibitors
Protein Inhibitors
DNA Inhibitors
Other Types of Inhibitors
Chapter 6 Market Breakdown, by Route of Administration
Global Market for Antibiotics by Route of Administration
Oral Antibiotics
Topical Antibiotics
Other Routes of Administration
Chapter 7 Market Breakdown, by Region
Global Market for Antibiotics by Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
R&D Changes
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in Pharma
Pharmaceutical Industry Growth Slowdown
Changes in Consumption Trends in Health-related Products
Chapter 9 Clinical Developments and Pipeline Products
Respiratory Tract Infections
Chapter 10 Value Chain Analysis
Introduction
China: Center of Microbial Threat
Chapter 11 Regulatory Scenario
FDA and International Regulation
Recent Regulatory Reforms
Ketek Case Study
Chapter 12 Competitive Landscape
Global Company Market Share Analysis
Mergers, Collaborations, Partnerships and Acquisitions
Chapter 13 Company Profiles
ABBOTT
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO. INC.
PFIZER INC.
SANOFI
VIATRIS INC.
Chapter 14 Appendix: Acronyms
List of Tables
Summary Table A : Global Market for Antibiotics, by Product, Through 2027
Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2027
Table 1 : Major Differences, Gram-Positive and Gram-Negative Organisms
Table 2 : Proportion of Resistant Strains, by WHO Region
Table 3 : Global Market for Antibiotics, by Product, Through 2027
Table 4 : Global Market for Cell Wall Inhibitor, by Product, Through 2027
Table 5 : Global Market for Cell Wall Inhibitors, by Region, Through 2027
Table 6 : Global Market for Protein Inhibitors, by Product, Through 2027
Table 7 : Global Market for Protein Inhibitors, by Region, Through 2025
Table 8 : Global Market for DNA Inhibitors, by Product, Through 2027
Table 9 : Global Market for DNA Inhibitors, by Region, Through 2027
Table 10 : Global Market for Other Types of Inhibitors, by Region, Through 2027
Table 11 : Global Market for Antibiotics, by Route of Administration, Through 2027
Table 12 : Global Market for Antibiotics, by Region, Through 2027
Table 13 : North American Market for Antibiotics, by Product, Through 2027
Table 14 : North American Market for Antibiotics, by Country, Through 2027
Table 15 : European Market for Antibiotics, by Product, Through 2025
Table 16 : European Market for Antibiotics, by Country, Through 2025
Table 17 : Asia-Pacific Market for Antibiotics, by Product, Through 2027
Table 18 : Asia-Pacific Market for Antibiotics, by Country, Through 2027
Table 19 : Latin American Market for Antibiotics, by Product, Through 2027
Table 20 : Latin American Market for Antibiotics, by Country, Through 2025
Table 21 : Middle Eastern and African Market for Antibiotics, by Product, Through 2027
Table 22 : Middle Eastern and African Market for Antibiotics, by Country, Through 2027
Table 23 : Antibiotics and Combinations in Global Clinical Development, Recent Approvals,2023
Table 24 : FDA-approved Antibacterial Drugs, 2018
Table 25 : FDA-Approved Antibacterial Drugs, 2019
Table 26 : Abbott: Antibiotics Product Portfolio
Table 27 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio
Table 28 : GlaxoSmithKline Plc: Antibiotics Product Portfolio
Table 29 : Johnson & Johnson: Antibiotics Product Portfolio
Table 30 : Merck & Co. Inc.: Antibiotics Product Portfolio
Table 31 : Merck & Co. Inc.: Antibiotic Drug Overview
Table 32 : Pfizer Inc.: Antibiotics Product Portfolio
Table 33 : Sanofi: Antibiotics Product Portfolio
Table 34 : Sanofi S.A.: Antibiotic Drugs Overview
Table 35 : Vitaris Inc.: Antibiotics Product Portfolio
Table 36 : Acronyms Used in this Report
List of Figures
Summary Figure A : Global Market Shares of Antibiotics, by Product, 2021
Summary Figure B : Global Market Shares of Antibiotics, by Route of Administration, 2021
Figure 1 : Types of Antibiotics, by Origin Source
Figure 2 : Share of API Manufacturing Facilities for All Drugs, by Country/Region, Aug. 2019
Figure 3 : Share of Population Aged 65+, by Region, 2019
Figure 4 : Forecasted Share of Population Aged 65+, by Region, 2050
Figure 5 : Increase in Elder Population, 2011 and 2050
Figure 6 : Distribution of Population with Hospital-acquired Infections, U.S., 2020
Figure 7 : Socioeconomic and Political Factors Contributing to Antibiotic Resistance
Figure 8 : Global Market Shares of Antibiotics, by Product, 2021
Figure 9 : Global Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 10 : Global Market for Cell Wall Inhibitors, by Region, 2021-2027
Figure 11 : Global Market Shares of Protein Inhibitors, by Product, 2021
Figure 12 : Global Market for Protein Inhibitors, by Region, 2019-2027
Figure 13 : Global Market Shares of DNA Inhibitors, by Product, 2019
Figure 14 : Global Market for DNA Inhibitors, by Region, 2019-2027
Figure 15 : Global Market for Other Types of Inhibitors, by Region, 2019-2027
Figure 16 : Global Market Shares of Antibiotics, by Route of Administration, 2021
Figure 17 : Global Market Shares of Antibiotics, by Region, 2021
Figure 18 : North American Market Shares of Antibiotics, by Product, 2021
Figure 19 : North American Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 20 : North American Market Shares of Protein Inhibitors, by Product, 2021
Figure 21 : North American Market Shares of DNA Inhibitors, by Product, 2021
Figure 22 : North American Market Shares of Antibiotics, by Country, 2022
Figure 23 : U.S. Market for Antibiotics, 2019-2027
Figure 24 : Canadian Market for Antibiotics, 2019-2027
Figure 25 : Mexican Market for Antibiotics, 2019-2027
Figure 26 : European Market Shares of Antibiotics, by Product, 2021
Figure 27 : European Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 28 : European Market Shares of Protein Inhibitors, by Product, 2021
Figure 29 : European Market Shares of DNA Inhibitors, by Product, 2021
Figure 30 : European Market Shares of Antibiotics, by Country, 2021
Figure 31 : German Market for Antibiotics, 2019-2027
Figure 32 : French Market for Antibiotics, 2019-2027
Figure 33 : U.K. Market for Antibiotics, 2019-2027
Figure 34 : Italian Market for Antibiotics, 2019-2027
Figure 35 : Spanish Market for Antibiotics, 2019-2027
Figure 36 : Rest of European Market for Antibiotics, 2019-2027
Figure 37 : Asia-Pacific Market Shares of Antibiotics, by Product, 2021
Figure 38 : Asia-Pacific Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 39 : Asia-Pacific Market Shares of Protein Inhibitors, by Product, 2021
Figure 40 : Asia-Pacific Market Shares of DNA Inhibitors, by Product, 2021
Figure 41 : Asia-Pacific Market Shares of Antibiotics, by Country, 2021
Figure 42 : Japanese Market for Antibiotics, 2019-2027
Figure 43 : Chinese Market for Antibiotics, 2019-2027
Figure 44 : Indian Market for Antibiotics, 2019-2027
Figure 45 : Australia and New Zealand Market for Antibiotics, 2019-2027
Figure 46 : Rest of Asia-Pacific Market for Antibiotics, 2019-2027
Figure 47 : Latin American Market Shares of Antibiotics, by Product, 2021
Figure 48 : Latin American Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 49 : Latin American Market Shares of Protein Inhibitors, by Product, 2021
Figure 50 : Latin American Market Shares of DNA Inhibitors, by Product, 2021
Figure 51 : Latin American Market Shares of Antibiotics, by Country, 2021
Figure 52 : Brazilian Market for Antibiotics, 2019-2027
Figure 53 : Argentinian Market for Antibiotics, 2019-2027
Figure 54 : Rest of Latin American Market for Antibiotics, 2019-2027
Figure 55 : Middle Eastern and African Market Shares of Antibiotics, by Product, 2021
Figure 56 : Middle Eastern and African Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 57 : Middle Eastern and African Market Shares of Protein Inhibitors, by Product, 2021
Figure 58 : Middle Eastern and African Market Shares of DNA Inhibitors, by Product, 2021
Figure 59 : Middle Eastern and African Market Shares of Antibiotics, by Country, 2021
Figure 60 : GCC Countries' Market for Antibiotics , 2019-2027
Figure 61 : South African Market for Antibiotics, 2021-2027
Figure 62 : Rest of Middle Eastern and African Market for Antibiotics, 2019-2027
Figure 63 : Impact of COVID-19 on the Pharmaceutical Industry
Figure 64 : Value Chain Analysis
Figure 65 : Global Market Shares of Antibiotics, by Manufacturer, 2021
Figure 66 : Abbott: Annual Revenue, 2019-2021
Figure 67 : Abbott: Revenue Shares, by Country/Region, 2021
Figure 68 : Abbott: Revenue Shares, by Business Unit, 2021
Figure 69 : F. Hoffmann-La Roche AG: Annual Revenue, 2019-2022
Figure 70 : F. Hoffmann-La Roche AG: Revenue Shares in Pharmaceutical Segment, by Country/Region, 2022
Figure 71 : F. Hoffmann-La Roche AG: Revenue Shares, by Business Segment, 2022
Figure 72 : F. Hoffmann-La Roche AG: Revenue Shares, by Therapeutic Segment, 2022
Figure 73 : GlaxoSmithKline Plc: Annual Revenue, 2020-2022
Figure 74 : GlaxoSmithKline Plc: Revenue Shares, by Pharmaceutical, 2022
Figure 75 : GlaxoSmithKline Plc: Revenue Shares, by Product Category, 2022
Figure 76 : GlaxoSmithKline Plc: Revenue Shares, by Region, 2022
Figure 77 : Johnson & Johnson: Annual Revenue, 2019-2021
Figure 78 : Johnson & Johnson: Revenue Shares, by Region, 2021
Figure 79 : Johnson & Johnson: Revenue Shares, by Business Unit, 2021
Figure 80 : Merck & Co. Inc.: Annual Revenue, 2020-2022
Figure 81 : Merck & Co. Inc.: Revenue Shares, by Region, 2019
Figure 82 : Merck & Co. Inc.: Revenue Shares, by Business Unit, 2019
Figure 83 : Pfizer Inc.: Annual Revenue, 2020-2022
Figure 84 : Pfizer Inc.: Revenue Shares, by Region, 2022
Figure 85 : Pfizer Inc.: Revenue Shares, by Country, 2022
Figure 86 : Pfizer Inc.: Revenue Shares, by Business Segment, 2022
Figure 87 : Sanofi: Annual Revenue, 2020-2022
Figure 88 : Sanofi: Revenue Shares, by Region/Country, 2022
Figure 89 : Sanofi: Revenue Shares, by Business Segment, 2022
Figure 90 : Viatris Inc.: Annual Revenue, 2020-2022
Figure 91 : Vitaris Inc.: Revenue Shares, by Region, 2022
Figure 92 : Vitaris Inc.: Revenue Shares, by Business Unit, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security